Arch Therapeutics Inc (NASDAQ:ARTH) has been assigned an average rating of “Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $2.83.

Several equities research analysts have commented on ARTH shares. Roth Capital set a $3.00 target price on shares of Arch Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 25th. Zacks Investment Research raised shares of Arch Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 25th. ValuEngine raised shares of Arch Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 3rd. HC Wainwright set a $3.00 target price on shares of Arch Therapeutics and gave the company a “buy” rating in a research note on Monday, June 12th. Finally, Ifs Securities reaffirmed an “outperform” rating on shares of Arch Therapeutics in a research note on Tuesday, July 25th.

Shares of Arch Therapeutics (NASDAQ:ARTH) opened at 0.796535 on Friday. The firm’s 50 day moving average is $0.74 and its 200-day moving average is $0.60. Arch Therapeutics has a 52 week low of $0.41 and a 52 week high of $0.89. The firm’s market cap is $117.11 million.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/16/arch-therapeutics-inc-arth-given-average-rating-of-buy-by-brokerages.html.

About Arch Therapeutics

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.